Kim Seth - Repare Therapeutics Executive Officer
| RPTX Stock | USD 3.32 0.17 5.40% |
Executive
Kim Seth is Executive Officer of Repare Therapeutics
| Address | 7171 Frederick-Banting, Building 2, Montreal, QC, Canada, H4S 1Z9 |
| Phone | 857 412 7018 |
| Web | https://www.reparerx.com |
Repare Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2339) % which means that it has lost $0.2339 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4117) %, meaning that it created substantial loss on money invested by shareholders. Repare Therapeutics' management efficiency ratios could be used to measure how well Repare Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.39 in 2024. Return On Capital Employed is likely to drop to -0.57 in 2024. At this time, Repare Therapeutics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 2.8 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 173 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Deborah MBA | Relay Therapeutics | N/A | |
| Todd Friedman | Accolade | N/A | |
| Mahesh Padval | Relay Therapeutics | N/A | |
| Don Osmer | 908 Devices | 59 | |
| Jim Watters | Relay Therapeutics | N/A | |
| Drew Garner | Accolade | N/A | |
| Kristen Bruzek | Accolade | N/A | |
| Jennifer Hanson | Accolade | N/A | |
| Eric JD | Nurix Therapeutics | 57 | |
| JD Esq | 908 Devices | 57 | |
| Kristin Herrera | Accolade | N/A | |
| Peter Rahmer | Relay Therapeutics | N/A | |
| Pasit Phiasivongsa | Nurix Therapeutics | N/A | |
| Brian JD | Relay Therapeutics | 50 | |
| James MD | Accolade | N/A | |
| Deborah Palestrant | Relay Therapeutics | N/A | |
| Christine JD | Nurix Therapeutics | 59 | |
| Cristiana Guiducci | Nurix Therapeutics | N/A | |
| Jason Kantor | Nurix Therapeutics | N/A | |
| MD MBA | Accolade | N/A | |
| Colin McHugh | Accolade | 45 | |
Management Performance
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.23 |
Repare Therapeutics Leadership Team
Elected by the shareholders, the Repare Therapeutics' board of directors comprises two types of representatives: Repare Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Repare. The board's role is to monitor Repare Therapeutics' management team and ensure that shareholders' interests are well served. Repare Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Repare Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Zinda, Executive Officer | ||
| Maria MD, Executive Officer | ||
| Agnel Sfeir, CoFounder | ||
| Cameron Black, Executive Discovery | ||
| Kim Seth, Executive Officer | ||
| Philip Herman, Ex Devel | ||
| Daniel Belanger, Executive Resource | ||
| Frank Sicheri, CoFounder | ||
| Daniel Durocher, CoFounder | ||
| Steve Forte, Executive CFO | ||
| Lloyd Segal, CEO President | ||
| Steve CPA, Executive CFO |
Repare Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Repare Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.26) % | ||||
| Operating Margin | (1.39) % | ||||
| Current Valuation | (42.96 M) | ||||
| Shares Outstanding | 42.51 M | ||||
| Shares Owned By Insiders | 0.95 % | ||||
| Shares Owned By Institutions | 83.62 % | ||||
| Number Of Shares Shorted | 749.74 K | ||||
| Price To Book | 0.77 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Repare Stock Analysis
When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.